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1. Introduction
  Stem cells from bone marrow, adipose tissue, blood and a 
few more sources are popular in regenerative medicine, as 
those have the self-renewal capacity and the potentiality 
for acting as progenitor cells. Bone marrow cells 
particularly, have the stroma with osteogenetic progenitor 
cells - mesenchymal stem cells (MSCs, 0.05%), apart from 
the hematopoietic component (hematopoietic stem cells or 
HSCs, 1% to 2%). 
   MSCs are popular for the capability of chondrogenic 
differentiation too and those could be expanded in culture 
through many generations. MSC therapy in combination 
with osteoconductive scaffold or osteoinductive protein 
as tools in regenerating bone fracture is reported from 
preclinical models of fracture healing[1,2]. Till date, there 
has been no standardized clinical translation of decades 
of preclinical investigations with animals on MSC therapy; 
nevertheless, bone fracture has always been an acute 
morbid condition. A viable protocol with MSC, for the 
holistic ‘bone healing’ with restoration of vascularity 
of the injured zone and bone-gap filling, without any 
opportunistic infection at the surgical site, is limited[3]. 
   Moreover, non-union in bone fractures nowadays has 
become a commonplace of orthopaedic treatment, a 
priory due to multiple unknown factors of which, polluted 
food could be a reason[4], and surgical site infection with 
multidrug resistant bacteria could be the other[5], as 
inveterately the surgeon prescribes antibiotics at the end 
of the surgical protocol. Secondly, at the fracture site, 
muscular and vascular tissues get sometimes heavily 
injured, limiting supply of blood for a long period, thereby 
limiting the supply of nutrients and influx of stem cells 
for the regeneration of the damaged tissue and progressive 
union of the bone fractures[6]. Eventually, a part of the 
tissue becomes dead and promotes cross infections. 
   This is a case report involving the use of in vitro cultured 
This is an attempt of using in vitro cultured mesenchymal stem cells (MSCs) from bone marrow in 
joining of a fracture non-union. Bone marrow cells were obtained and differentially centrifuged 
for MSCs that were grown in vitro in mesenchymal stem cell basal medium aseptically, for 10 d. 
The cell mass was injected around the fracture non-union. Healthy conditions of development of 
tissue regeneration at the trauma site and due bone joining were recorded. It is concluded that in 
vitro cultured MSCs had a blithesome effect on the fracture non-union.
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autologous bone marrow cells for bone-regeneration of a 
tibio-fibular non-union.
2. Case report
  Fractures of both tibia and fibula of a 28-year-old male 
were fixed with an interlocking nailing, previously in some 
other hospital; he was unable to walk without any support 
and the fracture site was tender till 8 months. The patient 
reported us with multiple discharges from the injured site 
that was addressed with dressing. 
  There were bacterial infections at the site, which 
were controlled by broad-spectrum-third-generation 
cephalosporins, cefuroxime and cefixime along with 
clavulanic acid. On an X-ray examination, the inadequate 
callus formation at the fracture site was evident (Figure 
1), hence the case was diagnosed as a non-union, which 
could be due to long-standing bacterial infection at the 
surgical site. Further, ‘autologous stem cell therapy’ with 
prior consent of the patient, following good manufacturing 
practice protocol and an approval through Institutional 
Ethical Committee was adopted. 
Figure 1. Prognosis of fracture non-union in X-ray plates following 
months of observation after injection of MSCs, after upper plate, 
1 month; middle plate, 3 months; and lower plate, 4 months. The 
arrowrepresents callus formation and reduction of gap at the end of 3 
months. 
 
  Following local anesthetization, an aliquot of 10 mL 
of bone marrow was harvested from the posterior iliac 
crest of the patient with a single puncture by an 11 gauge 
Jamshidi needle. The collected sample was heparinised, 
in a 50 mL size falcon tube and was further diluted with 
an aliquot of 10 mL of Dulbecco’s phosphate buffer saline 
(DPBS). Bone-marrow mononuclear cells (BMNCs) were 
isolated by differential centrifugation of the mixture with 
the lymphocyte separation medium (LSM), following the 
manufacturer’s protocol (HiMedia, Mumbai). 
   The pellet was washed with DPBS; cells were propagated 
in vitro with ‘mesenchymal stem cell basal medium’ (Stem 
Cell Technologies, Canada), in a CO2 incubator maintained 
at 37 曟 and 5% CO2. Cells were observed daily; medium 
was changed in alternate days up to the day 9 (Figure 2). 
   On the day 10, cells were collected from culture plate, 
manually dissociated by flushing. Those were washed two 
to three times with DPBS to remove traces of the medium, 
if any. 
  At an operation room, the patient was injected 
percutaneously with 1 mL of cultured stem cell mass (3×107 
cells/mL) into the site of non-union at 3-4 points with an 
18 gauge needle at several places around the non-union 
zone, under c-arm guidance. After 1 h of rest the patient 
was discharged and was instructed to report at monthly 
intervals. Significant soft callus formation was marked after 
one month and there was gradual progress in subsequent 
X-ray examination along with the reduction of the fracture 
gap (Figure 2). At the end of six months, the patient was 
able to walk without any support and had no pain. At 
length, the fracture gap was obliterated, evident in an 
X-ray film. 
Figure 2. Confluent growth of bone marrow stem cells (MSCs) under 
a phase contrast microscope on the day 7 of culture. 
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3. Discussion
  Use of MSCs in fracture healing and bone defects is 
a complex process, resulting in callus and bone tissue 
formation. It includes secretion of multiple factors in 
cascades of molecular events that often depend on 
nutritional status of patients, drugs administration, calcium 
balance, blood supply and stability of the fracture[7,8]. 
MSCs have precursors of osteoblasts and adipocytes, known 
as Westen-Bainton cells. 
   They regulate cellular growth and regeneration via 
secreting mechanisms during homeostasis and following an 
injury. The efficacy of MSCs in orthopaedics was known to 
be quite encouraging[8,9].
  In this case study, the patient with the non-union since 
8 months had obtained a significant clinical improvement 
in callus formation and tissue regeneration, following the 
injection of cultured autologous MSCs in a resource limited 
setting. Similar studies were also undertaken by animal 
models and humans[10]. 
  At certain instances, culture method was modified by 
using different scaffolds to obtain a sizable number of 
cells for a quicker healing. The infused pluripotent cells, 
herein MSCs at the fracture site may have both direct and 
indirect role in the repair mechanism. It was known that in 
order to obtain a successful fracture healing, blood vessels, 
growth factors, and proliferative precursor cells need to act 
simultaneously to cause an inductive healing effect[10]. 
  In addition to the cell proliferation, there was an 
enhancement of vasculature and a production of growth 
factors to convert the fibroblast into osteocytes, i.e., 
to trigger and harness the patient’s own regenerative 
mechanism. Thus, cultured MSCs could be used in future 
similar problems of regeneration of body parts[11]. However, 
further work is needed for the development of appropriate 
protocol for treating non-union cases. Thus, the use of in 
vitro grown stem cells in an acute disease of bone non-
union is epitomized herewith.   
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